WS13.2 Change in FEV1% predicted in one year in patients with nonsense mutations and patients homozygous for F508del  by De Boeck, K. et al.
Oral Presentations Workshop 13. New insights in lung disease S27
WS13.1 Patients with mutations that permit 3% or more of wild-type
CFTR function are associated with higher FEV1
P.R. Sosnay1, K.S. Raraigh1, F. Vangoor2, H. Yu2, C.M. Penland3, M. Corey4,
M.H. Lewis1, C. Castellani5, J. Rommens6, G.R. Cutting1, CFTR2 Study Group.
1Johns Hopkins University, Baltimore, United States; 2Vertex Pharmaceuticals
Incorporated, San Diego, United States; 3Cystic Fibrosis Foundation, Bethesda,
United States; 4The Hospital for Sick Children, Toronto, Canada; 5Cystic Fibrosis
Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; 6University of
Toronto, Toronto, Canada
Objectives: Quantifying the exact amount of CFTR function needed to escape
lung disease in CF has been challenging. Establishing a threshold above which
lung function improves provides a benchmark for molecular therapies that augment
CFTR function.
Methods: Clinical and genetic data were collected on 39,696 patients enrolled
in CF registries for the CFTR2 project. Functional consequences of 72 missense
CFTR mutations were determined by short circuit current in Fischer Rat Thyroid
cell lines expressing a single copy of CFTR cDNA. Mutations that introduce a
premature termination codon (PTC) were presumed to have <1% wild-type (WT)
CFTR function.
Results: Patients were grouped according to the function of their CFTR mutations
relative to WT (Table 1). Patients with two mutations each having <1% WT
CFTR function (includes F508del and PTC mutations) and patients with at least
one mutation of 3% CFTR function have a signiﬁcant difference in FEV1%
predicted. Patients with CFTR function 4−15% also had higher FEV1, but this was
not different than the 3% group.
Table 1. Comparison with <1%/<1%
<1%/<1% F508del/F508del <1%/1−2% <1%/2−3% <1%/3−4% <1%/4−15%
n 24947 16571 1459 241 134 612
Age 17.8±11.3 18.0±11.2 19.4±12.4** 19.7±12.0** 23.5±15.9** 24.2±16.7**
Sweat [Cl−] 101.8±16.1 101.9±15.6 102.7±16.3 99.8±16.7 79.9±25.0** 73.6±23.0**
Fraction PI 0.97 0.98 0.90** 0.77** 0.36** 0.37**
FEV1%pred. 74.3±25.3 74.5±25.3 75.2±24.6 73.3±23.9 82.6±27.0* 80.8±24.7**
*p< 0.05, **p< 0.001.
Conclusion: Patients with 3% CFTR function had a clinically relevant difference
in FEV1, along with differences in sweat chloride concentration and rates of
pancreatic insufﬁciency. These associations should be considered in evaluation of
molecular therapies directed at low function CFTR mutations.
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We are at the dawn of personalized medicine for patients with cystic ﬁbrosis (CF).
Several trials with mutation or mutation class speciﬁc drugs are ongoing. However,
it is unknown whether lung disease severity is worse in subjects with mutations
belonging to speciﬁc classes.
Using the 2008–2009 European Cystic Fibrosis Society Patient Registry data, we
evaluated the change in FEV1 % predicted in one year in subjects with CF (patients
6 years old or more, without lung transplant) and a baseline lung function between
40 and 90% predicted. We compared the change (2008 to 2009) in FEV1 %
predicted in subjects having at least one nonsense mutation (group I; n = 912) and
in subjects homozygous for F508del (group II; n = 3717). The change in FEV1
% predicted was similar in the two groups: the median of the change was −0.74%
predicted (IQR −5.93; +4.37) in group I, and −0.85% predicted (IQR −6.62; +4.61)
in group II. In group I the median change in FEV1 % predicted was positive in the
age categories 6−9 and 10−14 years, and negative from 15−19 up to 40−44 years; in
group II the median change of FEV1 % predicted was positive in the age categories
6−9 and 40−44 years, and negative from 10−14 up to 35−39 years. Expressed as
percentage from baseline year 2008, the median changes were 1.17% (IQR −9.35%;
6.38%) in group I and 1.29% (IQR −10.2%; +6.82%) in group II, again without
group differences (Kruskal-Wallis test: p = 0.59).
In conclusion, in patients with CF and baseline lung function between 40 and 90%
predicted, we did not ﬁnd evidence for difference in change in FEV1 % predicted
over 1 year between patients with nonsense mutations or patients homozygous for
F508del.
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Objectives: Recent studies in infants and preschool children with cystic ﬁbrosis (CF)
suggest that non-invasive monitoring will be important for patients who may beneﬁt
from early therapy to prevent structural lung damage. Magnetic resonance imaging
(MRI) detects structural and functional abnormalities in lungs from older CF patients
without radiation exposure. Aim of this study was to evaluate the potential of MRI to
detect abnormal lung structure and perfusion in infants and young children with CF,
and monitor response to therapy for pulmonary exacerbation.
Methods: MRI studies were performed in 50 children with CF (age 3.1±2.1years,
range 0−6years) in stable clinical condition (n = 40) or pulmonary exacerbation before
and after antibiotic treatment (n = 10), and in 26 non-CF controls (age 2.9±1.9years).
T1- and T2-weighted sequences before and after intravenous contrast and ﬁrst-pass
perfusion imaging were acquired, and assessed using a dedicated morpho-functional
score.
Results: MRI demonstrated bronchial wall thickening/bronchiectasis, mucus plugging
and perfusion deﬁcits from the ﬁrst year of life in most stable patients with CF (global
score 10.0±4.0), but not in non-CF controls (score 0.0±0.0; P < 0.001). In patients
with exacerbations, the global MRI score was increased to 18.0±2.0 (P < 0.001), and
was signiﬁcantly reduced to 12.0±3.0 (P < 0.05) after antibiotic therapy.
Conclusion: MRI detected abnormalities in lung structure and perfusion, and response
to therapy for exacerbations in infants and preschool children with CF. These results
support the development of MRI for non-invasive monitoring and as an endpoint in
interventional trials for early CF lung disease.
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Introduction: Little is known on the site and nature of CF small-airway disease
(SAD). Small airways can be studied at two levels of resolution: Multidetector
Computed Tomography scans (MDCT) with a resolution down to 1mm and
MicroComputed Tomography (mCT) to allow 3D morphometry of terminal bron-
chioles (TB) (<1mm in diameter).
Aim: To study SAD in CF using MDCT and mCT.
Methods: CF explant lungs (n = 8) and control lungs (n = 6) were inﬂated to
total lung capacity and ﬁxed in the fumes of liquid nitrogen. On MDCT and
utilizing Osirix 4.1, the number and diameter of visible and obstructed airways
were counted per airway generation (method: Verleden et al. AJRCCM 2013). Using
mCT (Skyscan 1172), the number per milliliter (mL), minimal diameter and cross-
sectional area (CSA) of TB were assessed in lung cores (on average 10/lung; each
core 1.5 cm diameter).
Results: CF lungs had signiﬁcantly more visible airways on MDCT than controls
(mean total 606 vs 316, p = 0.02). Airway dilatation was found downstream from
generation 6 with cumulative airway diameter of 209 cm per lung in CF versus
78 cm in controls (p = 0.004). Obstructive lesions were seen from generation 5−6
onwards; 75% (SD 20%) of total airways or around 40% of airways per generation
were obstructed. mCT showed a signiﬁcant reduction in the number (2.9 vs 5.6/mL;
p< 0.001), diameter (212 vs 363mm; p< 0.001) and CSA of TB (92 vs 177mm2;
p< 0.001) in CF versus control.
Conclusion:We studied CF SAD using MDCT and mCT. Dilatation and obstruction
of airways from generation 5−6 onwards as well as narrowing and disappearance of
TB were found. Ongoing research will correlate mCT TB lesions with histological
ﬁndings.
